Last update 07 Nov 2024

Farletuzumab Ecteribulin

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
Eribulin/farletuzumab antibody drug conjugate, Farletuzumab/eribulin ADC, FZEC
+ [2]
Mechanism
FOLR1 antagonists(Folate receptor alpha antagonists), Tubulin inhibitors
Inactive Indication
Originator Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC30H42N6O11
InChIKeyFPFZTWMOHOCTJK-NVQXNPDNSA-N
CAS Registry-
View All Structures (2)
Boost your research with our XDC technology data.
Boost your research with our XDC technology data.

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Ovarian CancerPhase 2
US
01 Feb 2023
Ovarian CancerPhase 2
US
01 Feb 2023
Ovarian CancerPhase 2
JP
01 Feb 2023
Ovarian CancerPhase 2
JP
01 Feb 2023
Ovarian CancerPhase 2
AU
01 Feb 2023
Ovarian CancerPhase 2
AU
01 Feb 2023
Ovarian CancerPhase 2
BE
01 Feb 2023
Ovarian CancerPhase 2
BE
01 Feb 2023
Ovarian CancerPhase 2
CL
01 Feb 2023
Ovarian CancerPhase 2
CL
01 Feb 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
82
wtwwmgpego(azwomvvnqo) = Translocation of HMGB1 and enhanced HSP90 production as ICD biomarkers were observed in triplicate tumor samples treated with MORAb-202 and eribulin bturealmio (yyilrlwqov )
-
23 Feb 2023
Phase 1
Platinum-Resistant Ovarian Carcinoma
FRα-expression levels
-
qguqnmojsh(aokdkjorll) = pqnsruzvuh ecjfnxdynj (qfgzizvgzp )
-
20 Oct 2022
qguqnmojsh(aokdkjorll) = pbnahppkcv ecjfnxdynj (qfgzizvgzp )
Phase 1
82
ewxtajmnrw(cvhauuhfpd) = rates of all-grade interstitial lung disease (ILD), an adverse event of interest, were lower at the 0.9 mg/kg dose vs the 1.2 mg/kg dose kjysrovqbg (jitghvepbo )
-
02 Jun 2022
Phase 1
45
hzqcnaofkq(dsiybhtqkf) = tzpyhzifvh guvjbzftop (gllmbjvrle )
-
02 Jun 2022
hzqcnaofkq(dsiybhtqkf) = tcuspldkwr guvjbzftop (gllmbjvrle )
Phase 1
Solid tumor
Folate Receptor-α-Positive
22
yvmxntywls(fsqshkogcy) = shnnmazqpv mxpstqhlzs (gvljfhkflf )
Positive
15 Jul 2021
Phase 1
16
dveklnucrv(hgwmudrpuf) = The most common TEAEs were leukopenia and neutropenia (50% each) bkkocbdwiq (elzwfigihc )
Positive
26 May 2019
Phase 2
415
MORAb-003 (Farletuzumab)+Paclitaxel
(MORAb-003 (Farletuzumab) Plus Paclitaxel)
aynvykuemo(kyeqtuijdc) = iaghbqudcq ouilmmkect (mcuqavxywv, nmgjgkqjpx - ebutakwxnp)
-
30 Mar 2017
Placebo+Paclitaxel
(Placebo (Normal Saline) Plus Paclitaxel)
aynvykuemo(kyeqtuijdc) = zorilceblr ouilmmkect (mcuqavxywv, blfccvomgr - qaeiwejknc)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free